$15.71
8.40% today
Nasdaq, Apr 04, 07:47 pm CET
ISIN
US15117B1035
Symbol
CLDX
Sector
Industry

Celldex Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Celldex Therapeutics, Inc. Classifications & Recommendation:

Buy
85%
Hold
15%

Celldex Therapeutics, Inc. Price Target

Target Price $61.00
Price $17.15
Potential
Number of Estimates 11
11 Analysts have issued a price target Celldex Therapeutics, Inc. 2026 . The average Celldex Therapeutics, Inc. target price is $61.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 11 Analysts recommend Celldex Therapeutics, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Celldex Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Celldex Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 7.02 3.67
2.03% 47.75%
EBITDA Margin -2,733.62% -6,417.83%
35.28% 134.77%
Net Margin -2,316.33% -5,932.51%
17.77% 156.12%

12 Analysts have issued a sales forecast Celldex Therapeutics, Inc. 2025 . The average Celldex Therapeutics, Inc. sales estimate is

$3.7m
Unlock
. This is
47.75% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$12.0m 70.94%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $7.0m 2.03%
2025
$3.7m 47.75%
Unlock
2026
$3.0m 17.67%
Unlock
2027
$43.0m 1,323.52%
Unlock
2028
$299m 595.21%
Unlock
2029
$740m 147.64%
Unlock

5 Analysts have issued an Celldex Therapeutics, Inc. EBITDA forecast 2025. The average Celldex Therapeutics, Inc. EBITDA estimate is

$-235m
Unlock
. This is
22.68% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-214m 11.40%
Unlock
, the lowest is
$-253m 31.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-192m 38.03%
2025
$-235m 22.68%
Unlock
2026
$-270m 14.75%
Unlock
2027
$-285m 5.41%
Unlock

EBITDA Margin

2024 -2,733.62% 35.28%
2025
-6,417.83% 134.77%
Unlock
2026
-8,945.70% 39.39%
Unlock
2027
-662.41% 92.60%
Unlock

12 Celldex Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Celldex Therapeutics, Inc. net profit estimate is

$-218m
Unlock
. This is
33.83% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-179m 10.16%
Unlock
, the lowest is
$-244m 49.80%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-163m 16.10%
2025
$-218m 33.83%
Unlock
2026
$-261m 19.87%
Unlock
2027
$-248m 4.90%
Unlock
2028
$-109m 56.23%
Unlock
2029
$184m 269.44%
Unlock

Net Margin

2024 -2,316.33% 17.77%
2025
-5,932.51% 156.12%
Unlock
2026
-8,638.00% 45.60%
Unlock
2027
-577.07% 93.32%
Unlock
2028
-36.33% 93.70%
Unlock
2029
24.86% 168.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.45 -3.28
16.10% 33.88%
P/E negative
EV/Sales 115.34

12 Analysts have issued a Celldex Therapeutics, Inc. forecast for earnings per share. The average Celldex Therapeutics, Inc. EPS is

$-3.28
Unlock
. This is
33.88% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.70 10.20%
Unlock
, the lowest is
$-3.67 49.80%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.45 16.10%
2025
$-3.28 33.88%
Unlock
2026
$-3.93 19.82%
Unlock
2027
$-3.74 4.83%
Unlock
2028
$-1.64 56.15%
Unlock
2029
$2.77 268.90%
Unlock

P/E ratio

Current -7.01 51.42%
2025
-5.23 25.39%
Unlock
2026
-4.36 16.63%
Unlock
2027
-4.59 5.28%
Unlock
2028
-10.48 128.32%
Unlock
2029
6.19 159.06%
Unlock

Based on analysts' sales estimates for 2025, the Celldex Therapeutics, Inc. stock is valued at an EV/Sales of

115.34
Unlock
and an P/S ratio of
310.35
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 60.27 81.85%
2025
115.34 91.37%
Unlock
2026
140.10 21.47%
Unlock
2027
9.84 92.98%
Unlock
2028
1.42 85.62%
Unlock
2029
0.57 59.62%
Unlock

P/S ratio

Current 162.18 58.73%
2025
310.35 91.37%
Unlock
2026
376.98 21.47%
Unlock
2027
26.48 92.98%
Unlock
2028
3.81 85.62%
Unlock
2029
1.54 59.62%
Unlock

Current Celldex Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Morgan Stanley
Locked
Locked
Locked Mar 20 2025
Goldman Sachs
Locked
Locked
Locked Mar 03 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 03 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 28 2025
UBS
Locked
Locked
Locked Feb 13 2025
Cantor Fitzgerald
Locked
Locked
Locked Jan 29 2025
Cantor Fitzgerald
Locked
Locked
Locked Jan 02 2025
Analyst Rating Date
Locked
Morgan Stanley:
Locked
Locked
Mar 20 2025
Locked
Goldman Sachs:
Locked
Locked
Mar 03 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 03 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 28 2025
Locked
UBS:
Locked
Locked
Feb 13 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jan 29 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jan 02 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today